



GOVERNMENT OF KHYBER PAKHTUNKHWA  
HEALTH DEPARTMENT  
REGIONAL BLOOD CENTRE (RBC) PESHAWAR



**SUBJECT: (MINUTES OF PRE-BID MEETING) FOR PROCUREMENT OF CONSUMABLES (KITS, MEDICAL DEVICES/BLOOD BAGS, ANTISERAS AND OTHERS) 2024-25 AT REGIONAL BLOOD CENTRE (RBC) PESHAWAR**

Meeting was chaired by Dr. Muhammad Nisar Khan, Chairman, Regional Blood Centre Peshawar.

**Participants:**

1. Dr. Muhammad Nisar Khan, Medical Officer, Regional Blood Centre, Peshawar
2. Dr. Ijaz Iqbal HEO/Genetic Counselor RBC Peshawar
3. Dr. Muhammad Idrees Khan, Quality Assurance Manager, RBC Peshawar
4. Mr. Muhammad Khalid Senior Clinical Technologist Food Laboratory KP
5. Mr. Samiul Haq Accounts/Admin Officer Regional Blood Center Peshawar
6. Bidders (list attached)

**Date:** 13<sup>th</sup> June 2024

**Venue:** Conference Hall, Regional Blood Centre (RBC), Hayatabad, Peshawar.

**Time:** 11:00 AM – 01:00 PM

The Procurement Committee supervised the Pre-bid meeting and welcomed all the participants. The meeting started with the recitation of the Holy Quran.

**DISCUSSIONS: -**

1. Meeting started with the vote of thanks from the chair.
2. Meeting was then proceeded, paying vote of thanks, and asking the bidding company members, to put forward their queries regarding the bidding documents for the financial year 2024-25.
3. All the representatives of bidders were briefed on the importance of pre-bid meeting to ensure fairness, transparency, competitiveness, accountability, economy and efficiency to achieve value for money in public procurement. The BSD was uploaded on websites of Health department and KP-PPRA from the date of advertisement for all prospective firms/bidders.
4. The bidders were informed that as per section 2(c)(i) the best evaluated responsive bid will be selected and the weightage of technical and financial will be as follow;
  - a. Technical bid weightage = 60 marks out of 100 and;
  - b. Financial bid Weightage = 40 marks out of 100.

The representatives of the firms were briefed that the specifications of goods are standardized and comprehensive, therefore, 60:40 is the best rationalized weightage to go with.

5. It was further explained that RBC Peshawar in this financial crunch of the province is not going to buy any equipment, therefore, as per previous analogy, the equipment will be placed by the firm/bidder at RBC on free of cost basis with CLIA kits. Moreover, when RBC is not buying any equipment, so there is no need to give detail specification of CLIA equipment rather the RBC will be assessing the quality output indicators of CLIA kits in technical evaluation criteria of BSD i.e. Sensitivity, specificity, Turnaround time and actual yield.
6. All representatives of the firm were in detail briefed regarding clauses of Bid data sheet to ensure healthy competition by ensuring efficient and effective bid submission. It was reiterated that conditions of Bid data sheet are as per previous analogy.
7. Queries were entertained from audience/ representatives of firms by the committee members after a threadbare discussion and unanimous decisions decided to incorporate the following changes as needed to ensure fair bidding, transparency and value for money.

**Address: RBC Hayatabad Phase IV Ph: 091-9217925 Email: [rbc.peshawar@gmail.com](mailto:rbc.peshawar@gmail.com)**



**GOVERNMENT OF KHYBER PAKHTUNKHWA**  
**HEALTH DEPARTMENT**  
**REGIONAL BLOOD CENTRE (RBC) PESHAWAR**



Sno	Name of Firm	Queries	Response
1.	<b>M/S Hoora Pharma</b>	Seek Clearance regarding section D-(CLIA) technical evaluation criteria concerning mandatory certificate number and other certificate numbers	The Procurement Committee has elucidated that one International certificate (JIS/WHO/US FDA/CE) is mandatory having 0 marks. 2 marks for each certificate issued by relevant forum after mandatory certificate mentioned in column 4 technical evaluation criteria proforma.
		Actual number of tests may kindly be elaborated as test/run instead of only test to clarify the misunderstanding	The procurement committee has unanimously decided to make a change in technical evaluation criteria and incorporated the same in column 17 for clarification in the best interest of public and patients.
		During physical evaluation, as mentioned in Technical evaluation criteria column-19, what parameters will be assessed?	The Procurement Committee clarified that all relevant parameters will be assessed.
		ISO Certificate may be consider collectively for all Section-D CLIA kits	After threadbare discussion the committee unanimously decided that every bidder has to submit separate ISO certificates for each kit/Item for section-D (CLIA)
2.	<b>M/S Sure Bio</b>	Will one Bid Security be acceptable for all Section?	As per advertisement one bid security will not be acceptable for all sections every bidder has to submit separate bid security for each section.
		What criteria will be followed for gel card for cross match selection will it be on FOC basis or otherwise?	The Procurement Committee after threadbare discussion explained that gel card for cross match will be on FOC basis.
		What will be stipulated time period for the supply of imported items?	The procurement Committee has clarified that imported items time period will be 90 days but being essential services, we can reduce this time period on need basis during emergency. So bidder has to ensure its stock accordingly.
3.	<b>M/S IBL Health Care</b>	Can IBL apply for two different brands for section A on single bid security?	The Committee explained that every bidder has to submit separate bid Security for the same item with different brands.
		Will both Blood Bags 500 ml or 450 ml be acceptable?	The Procurement Committee has explained both are acceptable and selection will be made on technical and financial grounds.
4.	<b>M/S ROCHE</b>	What will be the status of controls & calibration?	The Procurement Committee after threadbare discussion unanimously decided that controls and calibration will be provided on FOC basis as per standard quality policy.
5.	<b>M/S SMS</b>	Only manufacturer or manufacturer's authorized distributors be allowed.	The representative of firm was replied that the condition of considering sole agent is as per previous practice to ensure value for money and avoid the risk of restrictiveness and discrimination as per KP-PPRA to ensure healthy competition as per section 3 of KPPRA Act.
		Manufacturer or manufacturer authorized distributor registered with relevant tax bodies and having product registration in their own name.	Registration with relevant tax body is mandatory for all the firms/bidders. However, having product registration in their own name would make restrictiveness in the public procurement competition process, which is not allowed as per KP-PPRA. RBC is making compliance to the provisions of regulatory bodies.

**Address: RBC Hayatabad Phase IV Ph: 091-9217925 Email: [rbc.peshawar@gmail.com](mailto:rbc.peshawar@gmail.com)**



**GOVERNMENT OF KHYBER PAKHTUNKHWA**  
**HEALTH DEPARTMENT**  
**REGIONAL BLOOD CENTRE (RBC) PESHAWAR**



		Country of origin should be mentioned as Europe USA or Japan.	As explained, the technical specifications and evaluation criteria is so set forth to ensure highest quality assurance and compliance, therefore, adding restriction of “Europe USA or Japan” will be against the spirit of section 3 of KP-PPRA Act and competition commission Pakistan act.
		Required Instrument specification. Sheet is not included in SBD.	Already explained at point 5 above.
		Back up unit requirement.	The break down time for CLIA services is already on firm and in no circumstances the services at RBC will be hampered. Therefore, asking for back up unit will add on additional cost which in other way will be charged from RBC as Return on investment (ROI), therefore this suggestion is against the spirit of section 3 of KPPRA Act.
		The weightage calculation formula should be revised and more weightage should be given to technical score.	Already explained at point 4 above.
		International certification: JIS is Japanese industrial standard which is not specific to healthcare products, so not a relevant certification. Secondly, there is no brand in the market involving in blood donor screening kits.	The purpose of JIS was to encourage quality standards of Japan and not Japan country itself. Even a product manufactured in other country can acquire JIS certificate which is quality standards of Japan regardless of any specificity to healthcare. Moreover, every effort is made to avoid restrictiveness and discrimination and promote competition and openness, therefore, other certificates have been mentioned too with JIS to promote value for money.
		Latest Generation of the equipment offered by the manufacturer for desired purpose.	Already explained in point 5 above and is part of technical evaluation criteria.
		Notarization from the country of origin should be added.	Already part of BSD i.e. Section V. Technical Specifications, point 1(A)(i).
		Onboard reagent stability/expiry should be replaced with “Kits should include the calibrator reagent in the same integral to ensure the use of ease and sufficient kit contents.	As per KP-PPRA, RBC is bound to avoid restriction and discrimination in the specification and evaluation criteria, therefore, the already given criteria is as per KP-PPRA.

Note: As there is no substantial change in the Bid Solicitation documents and it remained same as was at the time of advertisement, therefore, no corrigendum or addendum is required as per KP-PPRA nor any firm/bidders asked for the same. As per Provision of KP-PPRA no additional document should be considered after bid opening date and time.